New eczema ointment shows promise in early trial

NCT ID NCT07629778

Recruiting now Symptom relief Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an ointment called HL-300 in people with mild-to-moderate atopic dermatitis (eczema). About 156 adults will apply the ointment or a placebo twice daily for 4 weeks. Researchers will check if the ointment reduces eczema severity and improves symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HL-300 ointment (a drug applied to the skin)
What this could lead to: If it works, this could provide a new topical treatment option to ease eczema symptoms like redness, itching, and skin damage.
What could go wrong: This is an early-phase trial with only 156 participants, so results may not apply to everyone. The ointment may not work better than placebo, and skin irritation or other side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS

Contacts and locations

Locations

Hangzhou First People's Hospital
RECRUITING

Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.